[{"id":"29940bae-2e04-4198-8582-ee2667059194","acronym":"","url":"https://clinicaltrials.gov/study/NCT06406465","created_at":"2024-05-11T04:14:20.188Z","updated_at":"2025-02-25T12:30:34.309Z","phase":"Phase 2","brief_title":"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity","source_id_and_acronym":"NCT06406465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-24"},{"id":"0dde1fb8-86ca-42a7-8591-8335a74747cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00045201","created_at":"2021-01-18T00:03:58.280Z","updated_at":"2025-02-25T13:51:49.237Z","phase":"Phase 1","brief_title":"Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00045201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["EGFR • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/13/2002","start_date":" 06/13/2002","primary_txt":" Primary completion: 09/13/2013","primary_completion_date":" 09/13/2013","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2025-02-20"},{"id":"c3ccbe27-3d9e-4190-a952-e531da2607f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890093","created_at":"2021-05-18T12:01:54.563Z","updated_at":"2025-02-25T13:49:09.588Z","phase":"Phase 1/2","brief_title":"Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT04890093","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-20"},{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"3006b5ef-d240-48dd-a833-44f7f7a000bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02138617","created_at":"2021-01-18T09:55:39.117Z","updated_at":"2025-02-25T16:36:22.191Z","phase":"Phase 2","brief_title":"Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02138617","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2025-02-06"},{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"1def5e25-f757-4960-ad8f-fdd1be50dd50","acronym":"","url":"https://clinicaltrials.gov/study/NCT03785873","created_at":"2021-01-18T18:43:16.171Z","updated_at":"2025-02-25T14:27:55.298Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT03785873","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 11/15/2024","study_completion_date":" 11/15/2024","last_update_posted":"2024-12-18"},{"id":"8e4c392a-1d29-432d-a4da-6bb8e1258676","acronym":"AG120-221-C-001","url":"https://clinicaltrials.gov/study/NCT02632708","created_at":"2021-01-17T17:12:58.212Z","updated_at":"2025-02-25T14:36:02.501Z","phase":"Phase 1","brief_title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","source_id_and_acronym":"NCT02632708 - AG120-221-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH1 • IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Tibsovo (ivosidenib) • daunorubicin • idarubicin hydrochloride • Idhifa (enasidenib) • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 12/31/2015","start_date":" 12/31/2015","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-07-25"},{"id":"1251a894-93e6-4c49-a11d-e5400df1cba5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05605509","created_at":"2022-11-04T16:58:13.524Z","updated_at":"2024-07-02T16:34:26.676Z","phase":"Phase 2","brief_title":"RP-6306 in Patients With Advanced Cancer","source_id_and_acronym":"NCT05605509","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • KRAS • TP53 • CCNE1 • UGT1A1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1","tags":["HER-2 • KRAS • TP53 • CCNE1 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (Debio2513)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-12"},{"id":"88d90e77-172d-4510-b158-f4795d53f576","acronym":"CRESCENDO","url":"https://clinicaltrials.gov/study/NCT06072131","created_at":"2023-10-10T15:12:06.102Z","updated_at":"2024-07-02T16:35:00.782Z","phase":"Phase 3","brief_title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","source_id_and_acronym":"NCT06072131 - CRESCENDO","lead_sponsor":"Acrotech Biopharma Inc.","biomarkers":" ALK • TNFRSF8 • UGT1A1","pipe":" | ","alterations":" TNFRSF8 expression • UGT1A1*1*1","tags":["ALK • TNFRSF8 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)"],"overall_status":"Recruiting","enrollment":" Enrollment 504","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 11/01/2030","study_completion_date":" 11/01/2030","last_update_posted":"2024-05-27"},{"id":"64c0eae1-673c-4049-a5b1-8479f1fe1ac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05683171","created_at":"2023-01-13T15:59:24.110Z","updated_at":"2024-07-02T16:35:04.648Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma","source_id_and_acronym":"NCT05683171","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1 • UGT1A1 mutation","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-09"},{"id":"66937713-e1c8-4e82-bb66-47047e56b479","acronym":"IDHENTIFY","url":"https://clinicaltrials.gov/study/NCT02577406","created_at":"2021-03-25T18:30:43.571Z","updated_at":"2024-07-02T16:35:06.839Z","phase":"Phase 3","brief_title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","source_id_and_acronym":"NCT02577406 - IDHENTIFY","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Idhifa (enasidenib) • hydroxyurea"],"overall_status":"Completed","enrollment":" Enrollment 319","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/25/2024","study_completion_date":" 03/25/2024","last_update_posted":"2024-04-30"},{"id":"7908f4df-7311-4c80-99de-b3ff9e5741f6","acronym":"TRIPP-FFX","url":"https://clinicaltrials.gov/study/NCT05466799","created_at":"2022-07-20T12:56:23.974Z","updated_at":"2024-07-02T16:35:10.029Z","phase":"Phase 2","brief_title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05466799 - TRIPP-FFX","lead_sponsor":"OncoSil Medical Limited","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/26/2023","start_date":" 04/26/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-04-11"},{"id":"6adec79d-70e3-4577-bae0-5f0e8b153dfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05678257","created_at":"2023-01-10T14:58:55.263Z","updated_at":"2024-07-02T16:35:11.773Z","phase":"Phase 2","brief_title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05678257","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF • UGT1A1","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • UGT1A1*1*1","tags":["KRAS • BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-03"},{"id":"11040b56-b83a-40c8-b335-611302ea384f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03720366","created_at":"2021-01-18T18:14:03.989Z","updated_at":"2024-07-02T16:35:17.394Z","phase":"Phase 1","brief_title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","source_id_and_acronym":"NCT03720366","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib) • midazolam hydrochloride • omeprazole"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 12/22/2023","study_completion_date":" 12/22/2023","last_update_posted":"2024-02-28"},{"id":"98b146c5-bd25-418a-a86a-b48aaa091bb5","acronym":"AG-221-C-001","url":"https://clinicaltrials.gov/study/NCT01915498","created_at":"2021-01-17T17:36:57.841Z","updated_at":"2024-07-02T16:35:19.804Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation","source_id_and_acronym":"NCT01915498 - AG-221-C-001","lead_sponsor":"Celgene","biomarkers":" IDH2 • UGT1A1","pipe":" | ","alterations":" IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation","tags":["IDH2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • UGT1A1*1*1 • Chr t(15;17) • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 345","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 07/25/2019","primary_completion_date":" 07/25/2019","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-02-12"},{"id":"9d2215ee-6fd7-46c1-bce0-de06efcc95e6","acronym":"FOLFIRINOX-R","url":"https://clinicaltrials.gov/study/NCT03828799","created_at":"2021-04-19T19:53:18.354Z","updated_at":"2024-07-02T16:35:19.989Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer","source_id_and_acronym":"NCT03828799 - FOLFIRINOX-R","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" UGT1A1","pipe":" | ","alterations":" RAS mutation • UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Stivarga (regorafenib) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 05/14/2019","start_date":" 05/14/2019","primary_txt":" Primary completion: 12/02/2021","primary_completion_date":" 12/02/2021","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-02-09"},{"id":"d2dc6321-01a2-4783-bd34-c34bd3bc5d9d","acronym":"GIANT","url":"https://clinicaltrials.gov/study/NCT04233866","created_at":"2021-01-18T20:35:40.191Z","updated_at":"2024-07-02T16:35:24.999Z","phase":"Phase 2","brief_title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","source_id_and_acronym":"NCT04233866 - GIANT","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" IL6 • UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["IL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 176","initiation":"Initiation: 08/26/2020","start_date":" 08/26/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-12-28"},{"id":"0ac2943a-4d67-4442-be19-a4505ba47397","acronym":"NEO-Nal- IRI","url":"https://clinicaltrials.gov/study/NCT03483038","created_at":"2021-01-18T17:09:31.835Z","updated_at":"2024-07-02T16:35:28.824Z","phase":"Phase 2","brief_title":"A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03483038 - NEO-Nal- IRI","lead_sponsor":"University of Florida","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 09/16/2023","primary_completion_date":" 09/16/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-11-18"},{"id":"588fb289-530f-4478-a18b-c0fb546696df","acronym":"Rapid 1","url":"https://clinicaltrials.gov/study/NCT04786600","created_at":"2021-03-08T12:53:45.858Z","updated_at":"2024-07-02T16:35:28.782Z","phase":"Phase 2","brief_title":"A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial","source_id_and_acronym":"NCT04786600 - Rapid 1","lead_sponsor":"University of Florida","biomarkers":" BRAF • MSI • UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["BRAF • MSI • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-11-18"},{"id":"ec44533f-4eb5-491d-92bc-8c763456a04b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010888","created_at":"2023-08-25T15:08:21.578Z","updated_at":"2024-07-02T16:35:39.030Z","phase":"Phase 2","brief_title":"Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC","source_id_and_acronym":"NCT06010888","lead_sponsor":"Fudan University","biomarkers":" BRAF • UGT1A1","pipe":" | ","alterations":" BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation","tags":["BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • Fruzaqla (fruquintinib) • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-08-25"},{"id":"e06060ec-f7b3-4249-8f3e-8a3fa8a80f7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05969899","created_at":"2023-08-01T15:10:04.615Z","updated_at":"2024-07-02T16:35:41.432Z","phase":"Phase 2","brief_title":"Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer","source_id_and_acronym":"NCT05969899","lead_sponsor":"Fudan University","biomarkers":" BRAF • UGT1A1","pipe":" | ","alterations":" BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation","tags":["BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation • UGT1A1*28 • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/10/2023","start_date":" 07/10/2023","primary_txt":" Primary completion: 07/10/2024","primary_completion_date":" 07/10/2024","study_txt":" Completion: 02/10/2027","study_completion_date":" 02/10/2027","last_update_posted":"2023-08-01"},{"id":"02a8700b-10e7-42d0-bae2-ac7f3065cf9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02022644","created_at":"2022-11-04T20:56:04.972Z","updated_at":"2024-07-02T16:35:44.339Z","phase":"Phase 1","brief_title":"Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma","source_id_and_acronym":"NCT02022644","lead_sponsor":"University of California, San Francisco","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 10/23/2014","start_date":" 10/23/2014","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2023-06-29"},{"id":"d4b8682b-1c56-42e4-a0d8-dc1a45eb1425","acronym":"ENSEMBLE","url":"https://clinicaltrials.gov/study/NCT05646511","created_at":"2022-12-12T15:00:16.382Z","updated_at":"2024-07-02T16:35:46.746Z","phase":"Phase 3","brief_title":"Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE)","source_id_and_acronym":"NCT05646511 - ENSEMBLE","lead_sponsor":"National Cancer Center Hospital East","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1 • UGT1A1 wild-type","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1 • UGT1A1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2023-05-31"}]